NCT02725112View on ClinicalTrials.gov

Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 12, 2016

Primary Completion Date

May 22, 2016

Study Completion Date

June 17, 2016

Conditions
Healthy
Interventions
DRUG

Pregabalin ER

A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.

DRUG

Pregabalin ER

B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.

DRUG

Pregabalin ER

C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.

DRUG

Pregabalin ER

D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.

DRUG

Pregabalin ER

E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.

DRUG

Pregabalin ER

F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.

Trial Locations (1)

06511

Pfizer New Haven Clinical Research Unit, New Haven

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT02725112 - Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers | Biotech Hunter | Biotech Hunter